False-negative rate for sentinel nodes high after neoadjuvant chemotherapy
October 7, 2013|Hematology and Oncology
Author and Disclosure Information
FROM THE ACS CLINICAL CONGRESS
The study was supported by a grant from the National Cancer Institute to the American College of Surgeons Oncology Group (ACOSOG). The patients were in the ACOSOG Z1071 trial. Four of the authors reported having grants from the National Institutes of Health or Komen Foundation, having contracts with Galena BioPharma, or having been paid for lectures from LifeCell. The remaining 17 authors said they had no relevant financial disclosures.
